- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Atezolizumab, Bevacizumab, Sorafenib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2545–2568
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C Virus Infection
- Interventions
- VOX, SOF/VEL, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 31
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
- Conditions
- Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
- Interventions
- As-needed follow up, Automatic follow-up
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 2,674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Mountain View, California • Palo Alto, California + 10 more
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Interventions
- filgrastim, docetaxel
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 33
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 26 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
- Interventions
- IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
- Conditions
- Atrial Fibrillation
- Interventions
- Patients with Atrial Fibrillation
- Other
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 13,769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 217
- States / cities
- Cullman, Alabama • Dothan, Alabama • Fairhope, Alabama + 214 more
- Conditions
- Major Depressive Disorder
- Interventions
- desvenlafaxine succinate sustained release, fluoxetine, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Acalabrutinib, Bortezomib, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Prednisone, Rituximab, Rituximab and Hyaluronidase Human
- Drug · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Charlotte, North Carolina • Seattle, Washington
- Conditions
- Clostridium, Difficile, Fidaxomicin, Vancomycin
- Interventions
- Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Lung Carcinoma
- Interventions
- Electronic Health Record Review, Interview, Patient Navigation
- Other · Behavioral
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,772 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Metformin, Matching Placebo
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- HIV Infections
- Interventions
- Globulin, Immune, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 48
- States / cities
- Downey, California • Long Beach, California • Los Angeles, California + 29 more
- Conditions
- Heart Failure With Left Bundle Branch Block
- Interventions
- aCRT ON, aCRT OFF
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,797 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 90
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 76 more
- Conditions
- Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 5 more
- Conditions
- Prostate Cancer
- Interventions
- MDX-010 / MDX-010 + Docetaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Long Beach, California • San Diego, California + 7 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Optune®
- Device
- Lead sponsor
- NovoCure Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 67 more
- Conditions
- Arginase I Deficiency, Hyperargininemia
- Interventions
- AEB1102
- Drug
- Lead sponsor
- Immedica Pharma AB
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Stanford, California • Gainesville, Florida • Detroit, Michigan + 3 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, etoposide, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 86
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Temozolomide, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newark, Delaware + 38 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SPD489
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 50
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, methotrexate, allogeneic bone marrow transplantation, iodine I 131 monoclonal antibody BC8, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 2 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- DSTP3086S
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- San Francisco, California • Chicago, Illinois • Detroit, Michigan + 2 more
- Conditions
- KRAS p.G12C Mutant Advanced Solid Tumors
- Interventions
- sotorasib, Anti PD-1/L1, Midazolam
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 29 more
- Conditions
- Acute Brain Injury, Pupillary Reflex Impaired
- Interventions
- pupillometry
- Other
- Lead sponsor
- University of Milano Bicocca
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- San Francisco, California • Baltimore, Maryland • Seattle, Washington